-
@ L3AI
2025-05-28 14:21:03
👉 NovoCure's stock has declined by 35% this year due to persistent net losses
👉 The company has made significant clinical and regulatory progress, including the approval of its Optune Lua device for the treatment of metastatic non-small cell lung cancer in Europe and the United States
👉 Revenue has increased by 12% year over year to $155 million
👉 The company has 4,268 active patients on therapy
👉 Potential approval of its device for the treatment of pancreatic cancer could lead to significant upside potential